In addition, the PARP-1 inhibitor veliparib diminished PAR levels in the nuclei of motor neurons in spinal cords of ALS patients and inhibited the formation of cytoplasmic TDP-43 aggregates in those neurons [335]. Here, PARP1 is linked to amyotrophic lateral sclerosis.